Review
Clinical Neurology
Xenia Gonda, Peter Dome, Joanna C. Neill, Frank Tarazi
Summary: The treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD) is still a major unmet need. Current drugs have limited efficacy or undesirable side effects. Developing novel antidepressant drugs beyond the monoamine targets may be an effective strategy to improve the treatment of MDD and TRD.
Review
Pharmacology & Pharmacy
Vincenzo Micale, Martina Di Bartolomeo, Serena Di Martino, Tibor Stark, Bernardo Dell'Osso, Filippo Drago, Claudio D'Addario
Summary: The etiopathogenesis of mental disorders involves multiple genetic factors and a tight association between genes and environmental risk factors mediated by epigenetic mechanisms. Epigenetic modifications such as DNA methylation, histone modification, and interference of microRNA or long non-coding RNA have been found to influence the severity of the disease and the outcome of therapy. Understanding these mechanisms can help identify vulnerable patients and serve as biomarkers for diagnosis and treatment of psychiatric disorders.
PHARMACOLOGY & THERAPEUTICS
(2023)
Review
Biochemistry & Molecular Biology
Malgorzata Jaronczyk, Jaroslaw Walory
Summary: This review provides an overview of molecular targets for antidepressants in the central nervous system (CNS) and computer-based strategies for discovering novel compounds with antidepressant activity.
Article
Psychology, Clinical
Jessica M. de Klerk-Sluis, Marloes J. Huijbers, Stephan Locke, Jan Spijker, Philip Spinhoven, Anne E. M. Speckens, Henricus G. Ruhe
Summary: The study found that cognitive reactivity (CR) and mindfulness were associated with relapse in remitted major depressive disorder (MDD) patients before the initiation of Mindfulness-based cognitive therapy (MBCT). Higher CR and lower mindfulness were found to increase the risk of relapse, while self-compassion and rumination were not associated with relapse. Particularly, for rumination, there was a significant interaction with the use of maintenance antidepressant medication, impacting its relationship with relapse.
DEPRESSION AND ANXIETY
(2022)
Review
Chemistry, Medicinal
Khushboo, Abhishek Kumar, Bechan Sharma
Summary: Depression is a common mental disorder, and plant-based compounds have gained attention as safe and efficient therapeutic agents for depression treatment. These compounds can regulate neurotransmitter levels and enzyme activities to exhibit antidepressant effects. Additionally, they possess antioxidative and anti-inflammatory properties, offering synergy in treating depression and psychiatric disorders.
MINI-REVIEWS IN MEDICINAL CHEMISTRY
(2022)
Review
Biochemistry & Molecular Biology
Ioannis Mantas, Marcus Saarinen, Zhi-Qing David Xu, Per Svenningsson
Summary: This review discusses the differences between traditional and atypical antidepressants, highlighting the potential for faster and more effective antidepressant actions through interaction with GPCRs. It also explores the role of GPCRs in regulating the pathophysiology of MDD and the therapeutic potential of novel GPCR targets. Recent advances in understanding GPCR pharmacology and structure are highlighted as potential avenues for drug development.
MOLECULAR PSYCHIATRY
(2022)
Article
Neurosciences
Jiewei Liu, Yuqi Cheng, Ming Li, Zhijun Zhang, Tao Li, Xiong-Jian Luo
Summary: Psychiatric disorders have a significant economic burden and limited effective drugs available. By integrating molecular and genetic data, we identified potential drug targets for psychiatric disorders and provided opportunities for new therapeutics development.
NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Medicine, General & Internal
Anna Mosiolek, Aleksandra Pieta, Slawomir Jakima, Natalia Zborowska, Jadwiga Mosiolek, Agata Szulc
Summary: Major depressive disorder is a prevalent mental illness worldwide, with more than 30% of patients not achieving remission through conventional therapy. Inflammation and disturbed neurogenesis are implicated in the pathophysiology of depression, with potential involvement of neurotrophic factors in patient recovery. The influence of antidepressants on inflammatory cytokines and neurotrophins remains inconsistent, with selective serotonin reuptake inhibitors, selective serotonin and noradrenaline inhibitors, and tricyclic antidepressants showing possible anti-inflammatory properties. Further research is needed to determine the role of inflammatory markers in predicting treatment response in MDD.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Medicine, General & Internal
Giulia Parpinel, Gianluca Rosso, Arianna Galante, Chiara Germano, Elena Aragno, Flavia Girlando, Alessandro Messina, Maria Elena Laudani, Alessandro Rolfo, Rossella Attini, Alberto Revelli, Giuseppe Maina, Bianca Masturzo
Summary: Depressive disorders in pregnant women lead to poorer outcomes, including higher rates of cesarean section, preterm delivery, induction of labor, low neonatal weights, and lower 5-min APGAR scores. Pharmacotherapy reduces the rate of cesarean section, but does not affect the 5-min APGAR scores, which are associated with neonatal weight.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Jian Liu, Zejun Guo, Meida Fan, Weihao Liang, Xin He, Dexi Wu, Yugang Dong, Wengen Zhu, Chen Liu
Summary: Limited data on depression in HFpEF patients and the efficacy of antidepressants. Study found no significant association between baseline major depression and cardiovascular outcomes in HFpEF patients. Treatment with antidepressants did not affect prognosis in HFpEF patients with major depression.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Psychiatry
Ivo H. Cerda, Paul J. Fitzgerald
Summary: The article presents a neurochemical model of unipolar major depressive disorder and predicts optimal pharmacological treatment based on different subtypes of depression. It suggests using different medications for high and low NE/5HT depression, and predicts the effects of rapidly acting antidepressants on different subtypes.
PSYCHIATRY RESEARCH
(2021)
Article
Clinical Neurology
Thibaut Gelle, Rayhanatou Altine Samey, Brigitte Plansont, Barbara Bessette, Marie-Odile Jauberteau-Marchan, Fabrice Lalloue, Murielle Girard
Summary: This study found that BDNF levels were decreased and proBDNF levels were increased in both serum and exosomes in patients with Major Depression (MD). During antidepressant treatment, there was an inverse relationship in the levels of BDNF and proBDNF in serum and exosomes. However, these levels were not related to clinical improvement or depression scales.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
(2021)
Article
Clinical Neurology
Ya-Mei Tzeng, I-Hsun Li, Hui-Han Kao, Jui-Hu Shih, Chin-Bin Yeh, Yi-Hsien Chen, Li-Ting Kao
Summary: This study found that antidepressants can reduce the subsequent risk of psoriasis in patients with major depressive disorder, particularly selective serotonin reuptake inhibitors and low-dose antidepressants have significant protective effects.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
Chiara Fabbri, Siegfried Kasper, Joseph Zohar, Daniel Souery, Stuart Montgomery, Diego Albani, Gianluigi Forloni, Panagiotis Ferentinos, Dan Rujescu, Julien Mendlewicz, Alessandro Serretti, Cathryn M. Lewis
Summary: Utilizing clinical risk factors to predict pharmacotherapy resistance and guide the prescription of pharmacotherapy combined with psychotherapy could be a cost-effective strategy, with CL-R showing better cost-effectiveness compared to PGx-CL-R in certain scenarios. The study suggests that using these predictors can help identify patients who are more likely to benefit from combined treatment, ultimately improving outcomes and reducing costs.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Article
Clinical Neurology
E. Papalexi, A. Galanopoulos, D. Roukas, I. Argyropoulos, I. Michopoulos, A. Douzenis, I. Gkolia, P. Fotiadis, D. Kontis, I. M. Zervas
Summary: Patients with MDD responding to antidepressant treatment still experience cognitive symptoms and functional impairment, especially in executive functioning. Concentration difficulties are common among responders. Patient-reported cognitive symptoms are significantly associated with functionality.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Article
Medicine, Research & Experimental
Ashish Dhir, Kanwaljit Chopra
Review
Pharmacology & Pharmacy
Ashish Dhir
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2017)
Article
Pharmacology & Pharmacy
Ashish Dhir, Vishal Chavda
PHARMACOLOGICAL REPORTS
(2016)
Review
Chemistry, Medicinal
Ashish Dhir
PHYTOTHERAPY RESEARCH
(2018)
Article
Pharmacology & Pharmacy
Ashish Dhir, Michael A. Rogawski
BRITISH JOURNAL OF PHARMACOLOGY
(2012)
Review
Pharmacology & Pharmacy
Lokesh Pathak, Yadvendra Agrawal, Ashish Dhir
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2013)
Review
Clinical Neurology
Ashish Dhir, Jayrajsinh Sarvaiya
EXPERT REVIEW OF NEUROTHERAPEUTICS
(2014)
Article
Pharmacology & Pharmacy
Ashish Dhir, Kanwaljit Chopra
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2015)
Article
Neurosciences
Ashish Dhir, Dorota Zolkowska, Michael A. Rogawski
Article
Neurosciences
Ashish Dhir, Christoph Lossin, Michael A. Rogawski
NEUROSCIENCE LETTERS
(2012)
Article
Neurosciences
Dorota Zolkowska, Ashish Dhir, Kathiresan Krishnan, Douglas F. Covey, Michael A. Rogawski
PSYCHOPHARMACOLOGY
(2014)
Review
Chemistry, Medicinal
Ashish Dhir
PHYTOTHERAPY RESEARCH
(2020)
Article
Toxicology
Dorota Zolkowska, Ashish Dhir, Michael A. Rogawski
Summary: The study found that perampanel and diazepam can effectively protect against TETS-induced tonic seizures and lethality, but have less impact on clonic seizures.
ARCHIVES OF TOXICOLOGY
(2021)
Article
Pharmacology & Pharmacy
A. Dhir
Article
Pharmacology & Pharmacy
Dorota Zolkowska, Christopher N. Banks, Ashish Dhir, Bora Inceoglu, James R. Sanborn, Mark R. McCoy, Donald A. Bruun, Bruce D. Hammock, Pamela J. Lein, Michael A. Rogawski
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(2012)